Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ..

Go back to Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ..
Bristol-Myers Squibb (NYSE: BMY) Delayed: 60.81 -0.87 (1.41%)
Previous Close $61.68    52 Week High $77.12 
Open $61.50    52 Week Low $49.03 
Day High $61.81    P/E 39.49 
Day Low $60.72    EPS $1.54 
Volume 2,404,763